- Pathophysiological notes for differentiation therapy of 5-azacytidine in MDS2014 | First Faculty of Medicine
- TRANSCRIPTION FACTOR PU.1 IS A TARGET OF 5-AZACITIDINE DURING DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMEPublication without faculty affiliation
- Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide2017 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- PU.1 Activation Relieves GATA-1-Mediated Repression of Cebpa and Cbfb during Leukemia Differentiation2009 | First Faculty of Medicine
- The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis2010 | First Faculty of Medicine
- Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia2019 | First Faculty of Medicine
- Possibilities and substantiation of re-treatment with anti-EGFR drugs for pre-treated RAS wild-type advanced colorectal cancers2021 | Publication without faculty affiliation
- Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 92006 | Second Faculty of Medicine